The Atomo Diagnostics Ltd (ASX: AT1) share price bolted more than 8% at one point during today’s session.
The medical device company finished the day up 4.55% at 23 cents.
Atomo shares have seen greater interest as Australia battles to control a new wave of COVID-19 infections.
Here’s why the Atomo share price is getting extra attention today.
Atomo share price up on COVID-19 rapid testing
The Atomo share price has come under the spotlight as the COVID-19 pandemic threatens to get out of hand in Australia.
Although Atomo has not released any price-sensitive news today, an article in The Australian could explain why shares in the biotech are racing higher.
The article highlighted the benefit of rapid antigen testing for COVID-19, as the outbreak in Australia worsens.
Australia has largely relied on pathology testing to detect positive cases and assist contact tracers.
However, given the rapid spread of the recent COVID-19 outbreaks, the need for rapid antigen testing has grown.
According to the article, rapid antigen tests can detect COVID-19 in as little as 10 minutes. By comparison, pathology testing can take up to three days to deliver a result.
In particular, the article highlighted the rapid COVID-19 test produced by Atomo.
The article noted that Atomo’s rapid tests have been supplied to various Olympic and sporting teams.
The tests have also been supplied to aged care providers.
The article also highlighted that Atomo has been supplying tests to the Australian Defence Force and mining and oil companies.
In the article, Atomo’s Chief Executive John Kelly said:
“And the problem is exacerbated by the fact that to get a product accepted in the state healthcare systems it really needs to be reimbursed. It’s been extremely difficult, nigh impossible, for point-of-care diagnostics to get reimbursement in Australia.”
More on the Atomo share price
Atomo is a medical device company that supplies rapid diagnostic test devices to the global diagnostic market. The company’s patented devices simplify testing procedures and enhance useability for professional users.
Of particular interest is Atomo’s CareStart EZ COVID-19 test.
CareStart EZ COVID-19 is a rapid antibody test, developed by Atomo in conjunction with its partner Access Bio.
Most recently, the Atomo share price received a boost after announcing that Access Bio received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for point-of-care use of its CareStart EZ COVID-19 test.
Shares in the medical device company hit an intraday high of 24 cents today.
The post Here’s why the Atomo (ASX: AT1) share price flew 4% higher today appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021
More reading
- The Atomo (ASX:AT1) share price has shot up 9%. Here’s why
- Ellume is making news and these ASX shares are surging, again
- Here’s why the Atomo (ASX:AT1) share price is soaring 10%
Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3jsr0XH
Leave a Reply